Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.
Metastatic, castration-resistant prostate cancer (mCRPC) directly contributes to the mortality and morbidity of prostate cancer. It is imperative to identify new molecular targets and discover effective therapeutic agents against lethal mCRPC. The …